Haleon plc (NYSE:HLN) Receives Average Rating of “Hold” from Brokerages

Shares of Haleon plc (NYSE:HLN) have received an average rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.95.

Several analysts have issued reports on the company. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. HSBC reissued a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research note on Monday, March 3rd.

Institutional Investors Weigh In On Haleon

Several hedge funds have recently made changes to their positions in HLN. Procyon Advisors LLC boosted its position in Haleon by 41.3% during the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock worth $2,196,000 after acquiring an additional 67,329 shares during the period. Jane Street Group LLC raised its stake in shares of Haleon by 1,689.4% in the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after acquiring an additional 250,169 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock worth $19,758,000 after buying an additional 475,934 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after acquiring an additional 1,026,939 shares during the period. Finally, SeaCrest Wealth Management LLC bought a new position in Haleon in the 4th quarter worth approximately $102,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

Shares of HLN stock opened at $10.19 on Monday. The firm has a fifty day simple moving average of $10.14 and a 200-day simple moving average of $9.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $45.99 billion, a PE ratio of 29.97, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon has a twelve month low of $8.12 and a twelve month high of $10.80.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Equities research analysts anticipate that Haleon will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a dividend yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.